Work

Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (adct‐301, Cami) in Relapsed/refractory (r/r) Classical Hodgkin Lymphoma (chl)

Year: 2019

Type: article

Source: Hematological Oncology

DOI: 10.1002/hon.61_2629

Authors: G. Collins, S. Horwitz, M. Hamadani, F. Samaniego, A. Spira, P. Caimi, A. Davies, T. Menne, P. Fields, H. Cruz, S. He, J. Boni, J. Feingold, J. Wuerthner, J. Radford

Institutions: Oxford University Hospitals NHS Trust, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The University of Texas MD Anderson Cancer Center, Virginia Cancer Specialists, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cancer Research UK, University of Southampton, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne Hospital, Guy's and St Thomas' NHS Foundation Trust, Adc Therapeutics (Switzerland), University of Manchester, The Christie NHS Foundation Trust

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2950167970

FWCI: 1.472

Cites:

Cited by: 8

Related to: 10